Mark Schoenberg, M.D., Named Chief Medical Officer Elyse Seltzer, M.D., Appointed Senior Vice President of Clinical Development RA`ANANA, Israel and NEW YORK, Dec. 12, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Mark Schoenberg, M.D., has been named Chief Medical Officer of UroGen, having previously served the Company as Medical Director. In addition, the Company announced the appointment of Elyse Seltzer, M.D., as UroGen`s Senior Vice President of Clinical Development. `We are thrilled to announce the expansion of...
|
